{"id":447830,"date":"2021-03-02T01:33:02","date_gmt":"2021-03-02T06:33:02","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=447830"},"modified":"2021-03-02T01:33:02","modified_gmt":"2021-03-02T06:33:02","slug":"nicox-provides-video-update-on-latest-developments","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nicox-provides-video-update-on-latest-developments\/","title":{"rendered":"Nicox Provides Video Update on Latest Developments"},"content":{"rendered":"
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n FOR INFORMATION<\/strong>\n <\/td>\n<\/tr>\n
Nicox Provides Video Update on Latest Developments<\/td>\n<\/tr>\n
\n \u00a0<\/strong><\/p>\n

March 2, 2021 \u2013 release at 7:30 am CET
Sophia Antipolis, France<\/p>\n

Nicox SA<\/strong> (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a brief video update on latest developments. <\/p>\n

Michele Garufi, Chairman and Chief Executive Officer of Nicox, <\/strong>discusses recent developments and planned upcoming milestones, including expected top-line results from two Phase 3 trials of lead product candidate NCX 470 for the treatment of glaucoma, as well as Phase 2b top-line results with NCX 4251 for the treatment of blepharitis and highlights the differentiation of these two product candidates from existing therapies.<\/p>\n

To access the video, click here<\/u><\/a>.<\/td>\n<\/tr>\n

\n About Nicox<\/strong>\n <\/td>\n<\/tr>\n
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.\u00a0 Nicox\u2019s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.\u00a0 The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.\u00a0 Nicox generates revenue from VYZULTA\u00ae <\/sup>in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE\u00ae<\/sup> in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.\u00a0 <\/p>\n

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. <\/p>\n

For more information on Nicox, its products or pipeline, please visit: www.nicox.com<\/u><\/a>.<\/u><\/td>\n<\/tr>\n

\n Analyst coverage<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/p>\n

Bryan, Garnier & Co \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Victor Floc\u2019h\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Paris, France
Cantor Fitzgerald\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Louise Chen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 New York, U.S.
Edison Investment Research Pooya Hemami\u00a0\u00a0\u00a0\u00a0\u00a0 London, UK
H.C. Wainwright & Co\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Yi Chen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 New York, U.S.
Kepler Cheuvreux\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Damien Choplain Paris, France<\/p>\n

\u00a0<\/em><\/td>\n

\u00a0<\/td>\n<\/tr>\n
\n The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. \u00a0Nicox disavows any obligation to correct or to update the information contained in analyst reports.<\/em>\n <\/td>\n<\/tr>\n
\n Contacts<\/strong>\n <\/td>\n<\/tr>\n
\n Nicox<\/strong>
\n
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development\u00a0
T +33 (0)4 97 24 53 00
communications@nicox.com <\/u><\/a><\/td>\n<\/tr>\n
Investors & Media
United States & Europe
LifeSci Advisors, LLC
Mary-Ann Chang
T +44 7483 284 853
mchang@lifesciadvisors.com<\/u><\/a><\/td>\n		Media
France
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
sophie@lifesciadvisors.com<\/u><\/a><\/td>\n<\/tr>\n
\n Forward-Looking Statements<\/strong>\n <\/td>\n<\/tr>\n
The information contained in this document may be modified without prior notice. \u00a0This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance.\u00a0 These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.\u00a0 Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.<\/p>\n

Risks factors which are likely to have a material effect on Nicox\u2019s business are presented in the 3rd<\/sup> chapter of the \u2018Document d\u2019enregistrement universel, rapport financier annuel et rapport de gestion 2020<\/em>\u2019 filed with the French Autorit\u00e9 des March\u00e9s Financiers<\/em> (AMF) on March 1, 2021 which are available on Nicox\u2019s website (www.nicox.com<\/u><\/a>).<\/td>\n<\/tr>\n

\n Nicox S.A.<\/strong>
\n
Drakkar 2
B\u00e2t D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99<\/td>\n<\/tr>\n<\/table>\n

\u00a0<\/p>\n

\n Attachment<\/strong>\n <\/p>\n